Category: Biosimilars
Biosimilars market research reports by DelveInsight
-
Etanercept – Biosimilar Insight, 2024
Etanercept – Biosimilar Insight, 2024 DelveInsight’s, “Etanercept – Biosimilar Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Etanercept pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. I ... Read More
-
Biosimilars- Market Insight, Competitive Landscape and Market Forecast- 2027
Biosimilars- Market Insight, Competitive Landscape and Market Forecast- 2027 Biosimilars Market By Product Class (Monoclonal Antibodies, Recombinant Hormone/Proteins, Anti-Inflammatory Agents, Immunomodulators, And Others), By Manufacturing Type (In-House And Outsourced/Contract), By Application (Au ... Read More
-
Ranibizumab biosimilars - Insight, 2022
DelveInsight’s, “ Ranibizumab Biosimilars – Pipeline Insight, 2022 ,” report provides comprehensive insights about 17+ companies and 17+ marketed and pipeline drugs in Ranibizumab Biosimilars pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. ... Read More
-
Etanercept– Biosimilar Insight, 2022
DelveInsight’s, “ Etanercept– Biosimilar 2022 ,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Etanercept Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers th ... Read More
-
Teriparatide– Biosimilar Insight, 2022
DelveInsight’s, “ Teriparatide– Biosimilar 2022 ,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Teriparatide Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also cover ... Read More
-
Follitropin alfa– Biosimilar Insight, 2022
DelveInsight’s, “ Follitropin alfa– Biosimilar 2022 ,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Follitropin alfa Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It al ... Read More
-
Ranibizumab-Biosimilars Insight, 2022
DelveInsight’s, “ Ranibizumab– Biosimilar 2022 ,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Ranibizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... Read More
-
Epoetin alfa– Biosimilar Insight, 2022
DelveInsight’s, “ Epoetin alfa– Biosimilar 2022 ,” report provides comprehensive insights about 15+ companies and 20+ marketed and pipeline drugs in Epoetin alfa Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also cover ... Read More
-
Filgrastim - Biosimilar Insight, 2022
DelveInsight’s, “ Filgrastim– Biosimilar 2022 ,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers th ... Read More
-
Somatotropin - Biosimilar Insight, 2022
DelveInsight’s, “ Somatropin– Biosimilar 2022 ,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Somatropin Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers th ... Read More
-
Adalimumab-Biosimilars Insight, 2022
DelveInsight’s, “ Adalimumab– Biosimilar 2022 ,” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Adalimumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers th ... Read More
-
Rituximab-Biosimilars Insight, 2022
DelveInsight’s, “ Rituximab– Biosimilar 2022 ,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Rituximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ... Read More
-
Insulin Glargine- - Biosimilar Insight, 2022
DelveInsight’s, “ Insulin Glargine– Biosimilar 2022 ,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It al ... Read More
-
Bevacizumab-Biosimilars Insight, 2022
DelveInsight’s, “ Bevacizumab– Biosimilar 2022 ,” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in Bevacizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... Read More
-
Infliximab-Biosimilars Insight, 2022
DelveInsight’s, “ Infliximab– Biosimilar 2022 ,” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers th ... Read More
-
Interferon - Biosimilar Insight, 2022
DelveInsight’s, “ Interferon– Biosimilar 2022 ,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Interferon Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers th ... Read More
-
Trastuzumab-Biosimilars Insight, 2022
DelveInsight’s, “ Trastuzumab– Biosimilar 2022 ,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... Read More
-
Darbepoetin alfa– Biosimilar Insight, 2022
DelveInsight’s, “ Darbepoetin alfa– Biosimilar 2022 ,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Darbepoetin alfa Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It al ... Read More
-
Pegfilgrastim– Biosimilar Insight, 2022
DelveInsight’s, “ Pegfilgrastim– Biosimilar 2022 ,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Pegfilgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also cov ... Read More
Research Assistance
